reports
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following...
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance...
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Foll...
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-’568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: ). The US$15 million payment will be fully recognized as revenue in the second qua...
Nxera Pharma Achieves Development Milestone in Collaboration with Eli ...
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requir...
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data f...
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 Tokyo, Japan and Cambridge, UK, 29 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona. For more information, please read Neuro...
Nxera Pharma Operational Highlights and Consolidated Results for the F...
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found . Chris Cargill, President and CEO of Nxera, commented: “As we mark one year since our transformation from Sosei Heptares to Nxera Pharma, I am incredibly proud of the progress we’ve made and how we have evolved. Our new identity has unified the Group and h...
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Regist...
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information, please read Neurocrine’s announcement () Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phas...
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya T...
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces the appointment of Shinya Tsuzuki, as Head of Investor Relations. Mr. Tsuzuki will lead Nxera’s Investor Relations (IR) team in Japan and report to the Company’s Chief Financial Officer, Hironoshin Nomura. Mr. Tsuzuki joins Nxera from Mizuho Securities, where he served as a Senior Investment Analyst and has covered the pharmaceutical and biotechnology sector since 2...
Nxera Pharma Announces Appointments to its Executive Leadership Team
Nxera Pharma Announces Appointments to its Executive Leadership Team Mr. Kiyoshi Kaneko appointed as Chief Commercial Officer, and Ms. Mariko Nakafuji promoted to Chief Legal Officer Tokyo, Japan and Cambridge, UK, 1 April 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces two new appointments to its Leadership team: Mr. Kiyoshi Kaneko, is appointed as Chief Commercial Officer (CCO), and Ms. Mariko Nakafuji is promoted into the role of Chief Legal Officer (CLO). Mr. Kaneko brings experience in business development, corporate strategy, marketing and commerci...
Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-30...
Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGluR5 negative allosteric modulator (NAM), for the treatment of alcohol use disorder (Clinical Trial ID: ). The full announcement from Tempero Bio can be found by , in which Tempero Bio also announces the close of a $70 million financing, the proceeds of which wi...
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexa...
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomniaFiling of daridorexant in Taiwan planned for 2025, and launch, if approved, is expected during 2026Daridorexant is launched in Japan as QUVIVIQ™ and is in Phase 3 trials in South Korea Tokyo, Japan and Cambridge, UK, 28 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has entered a license, supply and commercia...
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for...
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris Cenerimod is a novel oral S1P1 receptor modulator with potential to be a first- or best-in-class therapy for multiple autoimmune diseasesViatris previously acquired rights to cenerimod in all other territories from Idorsia, and now has exclusive global rightsNxera will receive an upfront payment of US$10 million from Viatris, and is eligible to receive a further milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales in the assigned territories Tokyo, J...
Nxera Pharma Proposes Changes to its Board of Directors
Nxera Pharma Proposes Changes to its Board of Directors Ms. Naoko Shimura and Ms. Nicola Rabson nominated for appointment as new External DirectorsMr. Shinichi Tamura, Mr. Tomohiro Tohyama and Mr. Kuniaki Kaga to retire from the Board of Directors Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated below. The nomination of candidates for External Directors is based on the resolution of the Nomination Committee. The appointments are expected to be...
Nxera Pharma Operational Highlights and Consolidated Results for the F...
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2024. The full report can be viewed . Chris Cargill, President & CEO of Nxera, commented: “2024 was a transformational year for Nxera during which we made excellent progress under our new company name and brand towards becoming a leading techno...
Nxera Pharma Webinar Presentation for FY2024 Financial Results
Nxera Pharma Webinar Presentation for FY2024 Financial Results Tokyo, Japan and Cambridge, UK, 23 January 2025 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2024 on Friday, 14 February 2025. The Company will host a live webinar presentation with Chris Cargill, President and CEO, Hironoshin Nomura, CFO, Matt Barnes, President of Nxera Pharma UK and Head of UK R&D and Makoto Sugita, President of Nxera Pharma Japan and Chief Medical Officer, at 5:00 pm JST (8:00 am GMT) on Friday, 14 February 2...
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partner...
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) regarding the clinical development of its partnered muscarinic agonist portfolio. These updates were presented by Neurocrine at the 43rd Annual J.P. Morgan Healthcare Conference. The update presented by Neurocrine included the following information: An End of Phase 2 meeting for NBI-1117568 (...
Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conf...
Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Chris Cargill, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, 15 January 2025 at 3:00 p.m. PST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this . Presentation slides will be made available through ...
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Ins...
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd. (“Shionogi”) today announce that QUVIVIQ™ (daridorexant) 25 and 50 mg has been launched and is now available in Japan as a new treatment for adults with insomnia. QUVIVIQ™ is an oral Dual Orexin Receptor Antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin ...
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Tr...
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomniaQUVIVIQ™ (daridorexant) 25 and 50 mg was recently approved and is expected to launch in Japan in Q4 2024 Tokyo, Japan and Cambridge, UK, 5 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces randomization of the first patient in a Phase 3 clinical trial evaluating daridorex...
Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a...
Nxera Pharma’s Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes that Centessa Pharmaceuticals has initiated a Phase 2 trial of ORX750, an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of na...
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Ta...
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-lear...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.